Drug Profile
Soluble beta-1,3/1,6-glucan
Alternative Names: SBG; Soluble beta-glucan; WoulganLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Biotec Pharmacon
- Class Antineoplastics; Beta Glucans
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer; Stomatitis
Highest Development Phases
- No development reported Breast cancer; Inflammatory bowel diseases; Influenza virus infections; Neuroblastoma; Non-Hodgkin's lymphoma; Stomatitis
- Discontinued Diabetic foot ulcer
Most Recent Events
- 15 Sep 2015 No recent reports on development identified - Phase-I for Non-Hodgkin's lymphoma (Combination therapy) in Norway (PO)
- 15 Sep 2015 No recent reports on development identified - Phase-I/II for Neuroblastoma (Combination therapy, In children) in USA (PO)
- 15 Sep 2015 No recent reports on development identified - Preclinical for Inflammatory bowel disease in Norway (PO)